The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| WUXI.F | +301.95% | +36.34% | +6.35% | +26% |
| S&P | +19.89% | +109.18% | +15.89% | +170% |
WuXi AppTec Co., Ltd. provides an integrated pharmaceutical platform for the research, development, and production of new drugs. It operates through the following business segments: Contract research organization (CRO) services, Contract manufacturing organization (CMO)/Contract development and manufacturing organization (CDMO) business, and Others. The CRO services segment includes laboratory services in China, laboratory services in the United States, and clinical research services. The company was founded by Ge Li, Ning Zhao, Xiao Zhong Liu, Zhao Hui Zhang, and Tao Lin on December 1, 2000 and is headquartered in Shanghai, China.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.68B | 15.3% |
| Gross Profit | $837.28M | 36.5% |
| Gross Margin | 49.75% | 7.7% |
| Market Cap | $39.14B | 261.0% |
| Market Cap / Employee | $1.03M | 0.0% |
| Employees | 37.8K | 0.0% |
| Net Income | $495.69M | 53.1% |
| EBITDA | $657.17M | 50.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.58B | 171.2% |
| Accounts Receivable | $1.62B | 5.1% |
| Inventory | 971.4 | 53.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $327.57M | -44.1% |
| Short Term Debt | $949.15M | 123.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 19.11% | 6.7% |
| Return On Invested Capital | 15.45% | 2.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $370.91M | 9.5% |
| Operating Free Cash Flow | $574.35M | 20.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 15.18 | 15.65 | 13.98 | 19.47 | 33.41% |
| Price to Book | 2.48 | 2.85 | 2.40 | 4.70 | 226.48% |
| Price to Sales | 3.73 | 4.27 | 4.70 | 6.68 | 93.72% |
| Price to Tangible Book Value | 2.61 | 2.99 | 2.46 | 4.82 | 218.16% |
| Price to Free Cash Flow TTM | 26.93 | 27.69 | 33.79 | 54.10 | 83.92% |
| Enterprise Value to EBITDA | 50.31 | 48.91 | 50.26 | 55.73 | 44.88% |
| Free Cash Flow Yield | 3.7% | 3.6% | 3.0% | 1.8% | -45.63% |
| Return on Equity | 19.7% | 21.7% | 26.5% | 25.6% | 50.46% |
| Total Debt | $1.17B | $1.37B | $1.54B | $1.28B | 26.34% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
